Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer
PHASE3CompletedINTERVENTIONAL
Enrollment
180
Participants
Timeline
Start Date
June 30, 1999
Conditions
Lung Cancer
Interventions
DRUG
Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.
All Listed Sponsors
lead
West Japan Thoracic Oncology Group
OTHER
NCT00148291 - Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter